Inhibrx Biosciences Inc.
INBX
NASDAQ
Healthcare
$97.58
+2.78%gain today
Market position
Market cap rank
#2333
of 2,614
1-day
+2.78%
1-month
+4.22%
6-month
+23.52%
YTD
+30.04%
1-year
+519.95%
5-year
+235.44%
Key figures
Market cap
$1.43B
P/E (live)
—
price ÷ annual EPS
P/E (reported)
-8.7
FY 2025
EPS
-$9.04
FY 2025
Dividend yield
0.00%
FY 2025
Dividend / share
$0.85
Gross margin
-91.00%
FY 2025
Operating margin
-10,386.54%
FY 2025
Net margin
-10,773.46%
FY 2025
Return on equity
—
FY 2025
Valuation & financial health
Enterprise value
$1.21B
FY 2025
EV / EBITDA
-9.10
FY 2025
EV / Sales
927.90
FY 2025
Price / book
153.07
FY 2025
Price / sales
941.13
FY 2025
Earnings yield
-11.45%
FY 2025
FCF yield
-10.61%
FY 2025
Debt / equity
13.39
FY 2025
Current ratio
3.93
FY 2025
Return on assets
—
FY 2025
Return on invested capital
Financials · FY 2025
Revenue
$1.3M
Gross profit
$-1.18M
Operating income
$-135.03M
EBITDA
$-132.54M
Net income
$-140.06M
Diluted EPS
-$9.04
Shares outstanding
15,487,000
Trading
Open
$96.40
Previous close
$94.94
Day range
$91.37 – $97.59
52-week range
$15.83 – $155.29
50-day avg
$106.96
200-day avg
$78.07
Volume
201,418
Avg volume
450,940
Beta
3.43
Price history
+519.95% over 1Y
Compare with peers
About Inhibrx Biosciences Inc.
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
Visit websiteCompany info
CEO
Mark Lappe
IPO date
May 29, 2024
Headquarters
La Jolla, CA, US
Country
Fundamentals are annual. Figures labeled with their fiscal year.
